Search
Hengrui Medicine Secures Approval for Clinical Trials of Remimazolam Tosylate Injection
3 day ago /
Read about 0 minute
Author：小编
Hengrui Medicine has announced that its Remimazolam Tosylate Injection has received approval from the National Medical Products Administration (NMPA) to initiate clinical trials for sedation in pediatric and adolescent patients aged 3 to 17 undergoing general anesthesia surgery. As a short-acting agonist of the GABAa receptor, Remimazolam Tosylate boasts rapid onset and a short recovery time, making it a promising candidate for this indication. To date, the project has invested approximately RMB 173 million in research and development. However, before the product can be officially launched onto the market, further clinical trials and regulatory approval processes must be successfully completed.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
